RecruitingNCT06678724

Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip

Sponsor

National Taiwan University Hospital

Enrollment

30 participants

Start Date

Jan 1, 2025

Study Type

OBSERVATIONAL

Conditions

Recurrent Head and Neck Squamous Cell Carcinoma Head and Neck Cancers- Squamous Cell Head and Neck Cancer Metastatic

Summary

The goal of this observational study is to learn about the prognostic value of circulation tumor emboli (CTM) in recurrent/metastatic head and neck cancer patients and also the changes of tumor microenvironment by different treatment modalities and drugs. The main questions it aims to answer are: 1. Investigators plan to correlate circulating tumor cells (CTC), circulating tumor emboli (CTM), and the composition of NK cells in CTM with clinical outcomes and establish their association with patient prognosis. 2. Investigators plan to understand the composition of NK cells and the immune cell components within CTM, and correlate these findings with treatment efficacy. Patients with recurrent/metastatic head and neck cancer will be included after informed consent and investigators will collect blood samples for analysis from them under the treatment provided by their primary care physicians.

Eligibility

Min Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This study develops a blood test platform using a microfluidic chip (a tiny lab-on-a-chip device) to detect cancer cells and immune activity in the blood of people with recurrent or metastatic head and neck cancer. The goal is to find a minimally invasive way to track cancer progression and predict outcomes. **You may be eligible if...** - You are 20 or older - You have confirmed squamous cell carcinoma of the head or neck (oropharynx, oral cavity, hypopharynx, or larynx) that is recurrent or metastatic - Your performance status is adequate (ECOG 0–2) - You are willing to provide blood samples for analysis **You may NOT be eligible if...** - You have another type of head and neck cancer (not squamous cell) - Your performance status is too poor to participate - You have active serious infections or conditions that interfere with blood testing Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

National Taiwan University HsinChu Branch

Zhubei, HsinChu County, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06678724

Related Trials

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

NCT04671667177 locations

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

NCT06589804176 locations

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

NCT066620581 location

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

NCT069800385 locations

Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma

NCT072139341 location